
Overview
Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar.
Dr. Lam is highly rated in 9 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer.
His clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Residency
Specialties
Licenses
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Kimmel Cancer Center, Baltimore, MD 21224
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Office
Taofeek Owonikoko is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.
Johns Hopkins Bayview Medical Center
Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is highly rated in 13 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.
Frequently Asked Questions about Dr. Vincent Lam
How do I make an appointment with Dr. Vincent Lam?
You can book an appointment with Dr. Vincent Lam by calling their office at 410-550-1711. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Vincent Lam a top-rated expert for Pleuropulmonary Blastoma?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vincent Lam is classified as an Distinguished expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Vincent Lam specialize in?
While Dr. Vincent Lam is a Oncology, they have specific expertise in Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Vincent Lam participate in research or clinical trials?
Yes. Dr. Vincent Lam has published 1 articles and abstracts on conditions like Pleuropulmonary Blastoma. You can view a list of Dr. Vincent Lam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Vincent Lam accept my insurance?
Dr. Vincent Lam accepts most major insurance plans, including Aetna and Capital Blue Cross. We recommend calling the office directly at 410-550-1711 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- ALK-Positive Non-Small Cell Lung Cancer
- Lung CancerDr. Lam isDistinguished. Learn about Lung Cancer.
- Pleuropulmonary BlastomaDr. Lam isDistinguished. Learn about Pleuropulmonary Blastoma.
- Small Cell Lung Cancer (SCLC)Dr. Lam isDistinguished. Learn about Small Cell Lung Cancer (SCLC).
- Squamous Cell Lung CarcinomaDr. Lam isDistinguished. Learn about Squamous Cell Lung Carcinoma.
- Advanced
- EGFR Positive Lung CancerDr. Lam isAdvanced. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Lam isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Lam isAdvanced. Learn about Lung Adenocarcinoma.
- Non-Small Cell Lung Cancer (NSCLC)
- Experienced
- DehydrationDr. Lam isExperienced. Learn about Dehydration.
- MesotheliomaDr. Lam isExperienced. Learn about Mesothelioma.
- Metastatic Brain TumorDr. Lam isExperienced. Learn about Metastatic Brain Tumor.
- Metastatic Pleural TumorDr. Lam isExperienced. Learn about Metastatic Pleural Tumor.
- Paris-Trousseau ThrombocytopeniaDr. Lam isExperienced. Learn about Paris-Trousseau Thrombocytopenia.
- Posterior Fossa TumorDr. Lam isExperienced. Learn about Posterior Fossa Tumor.

